MX2023009475A - Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. - Google Patents
Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer.Info
- Publication number
- MX2023009475A MX2023009475A MX2023009475A MX2023009475A MX2023009475A MX 2023009475 A MX2023009475 A MX 2023009475A MX 2023009475 A MX2023009475 A MX 2023009475A MX 2023009475 A MX2023009475 A MX 2023009475A MX 2023009475 A MX2023009475 A MX 2023009475A
- Authority
- MX
- Mexico
- Prior art keywords
- indole
- chloro
- cancer
- mcl
- inhibitors
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 3
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- RQHISNLHWQDLSZ-UHFFFAOYSA-N OC(C(NC1=C2C3=CN=CN=C3)=CC1=CC=C2Cl)=O Chemical class OC(C(NC1=C2C3=CN=CN=C3)=CC1=CC=C2Cl)=O RQHISNLHWQDLSZ-UHFFFAOYSA-N 0.000 title 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 241001326189 Gyrodactylus prostae Species 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000002611 ovarian Effects 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se relaciona con compuestos de la Fórmula (I) en donde XI es como inhibidores de leucemia de células mieloides 1 (MCL-1) para el tratamiento del cáncer, tal como, p. ej., cáncer de próstata, pulmón, páncreas, mama, ovario, y cuello uterino, melanoma, leucemia linfocítica crónica de células B (CLL), leucemia mieloide aguda (AML), y leucemia linfoblástica aguda (ALL). Un compuesto ilustrativo es, p. ej., el Compuesto 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21156777 | 2021-02-12 | ||
| PCT/EP2022/053340 WO2022171782A1 (en) | 2021-02-12 | 2022-02-11 | Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009475A true MX2023009475A (es) | 2023-08-22 |
Family
ID=74595116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009475A MX2023009475A (es) | 2021-02-12 | 2022-02-11 | Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4291564A1 (es) |
| JP (1) | JP2024506648A (es) |
| KR (1) | KR20230145079A (es) |
| CN (1) | CN116848126A (es) |
| AU (1) | AU2022220818A1 (es) |
| CA (1) | CA3206202A1 (es) |
| MX (1) | MX2023009475A (es) |
| WO (1) | WO2022171782A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180499A (es) | 2016-04-22 | 2019-01-25 | Astrazeneca Ab | Inhibidores de mcl1 macrocicliclos para tratar el cancer |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| WO2020063792A1 (zh) | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| EP3781570A4 (en) | 2018-11-22 | 2021-06-02 | Ascentage Pharma (Suzhou) Co., Ltd. | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS |
| CN114641481A (zh) * | 2019-06-21 | 2022-06-17 | 詹森药业有限公司 | Mcl-1的大环抑制剂 |
-
2022
- 2022-02-11 MX MX2023009475A patent/MX2023009475A/es unknown
- 2022-02-11 WO PCT/EP2022/053340 patent/WO2022171782A1/en active Application Filing
- 2022-02-11 KR KR1020237027993A patent/KR20230145079A/ko unknown
- 2022-02-11 EP EP22705394.9A patent/EP4291564A1/en active Pending
- 2022-02-11 AU AU2022220818A patent/AU2022220818A1/en active Pending
- 2022-02-11 JP JP2023548588A patent/JP2024506648A/ja active Pending
- 2022-02-11 CN CN202280014545.0A patent/CN116848126A/zh active Pending
- 2022-02-11 CA CA3206202A patent/CA3206202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024506648A (ja) | 2024-02-14 |
| AU2022220818A1 (en) | 2023-09-28 |
| CA3206202A1 (en) | 2022-08-18 |
| CN116848126A (zh) | 2023-10-03 |
| WO2022171782A1 (en) | 2022-08-18 |
| EP4291564A1 (en) | 2023-12-20 |
| KR20230145079A (ko) | 2023-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009372A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020551507A1 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| MX2021003442A (es) | Regulador de derivados heteroaromaticos que contienen nitrogeno, metodo de preparacion y uso de los mismos. | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2021006026A (es) | Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos. | |
| GEP20227359B (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| SG132672A1 (en) | 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| GEP20115304B (en) | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2023004373A (es) | Metodos y composiciones para la degradacion dirigida de proteinas. | |
| MX2022011407A (es) | Compuestos para tratar o inhibir la recidiva de la leucemia mieloide aguda. | |
| CR20220478A (es) | Derivados de benzodiazepinas como pam de gaba a gamma 1 | |
| RU2011134283A (ru) | Имидазотиазольные производные, имеющие пролиновую циклическую структуру | |
| MX2023000150A (es) | Compuesto de sulfonamida. | |
| MX2023009475A (es) | Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| CR20230382A (es) | Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. |